JP2016539983A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016539983A5 JP2016539983A5 JP2016537963A JP2016537963A JP2016539983A5 JP 2016539983 A5 JP2016539983 A5 JP 2016539983A5 JP 2016537963 A JP2016537963 A JP 2016537963A JP 2016537963 A JP2016537963 A JP 2016537963A JP 2016539983 A5 JP2016539983 A5 JP 2016539983A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- chloro
- fluoro
- compound
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 32
- 125000001309 chloro group Chemical group Cl* 0.000 claims 10
- 125000001153 fluoro group Chemical group F* 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- -1 C 1 -C 6 alkoxy Chemical group 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010037549 Purpura Diseases 0.000 claims 1
- 241001672981 Purpura Species 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 208000024340 acute graft versus host disease Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000017760 chronic graft versus host disease Diseases 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000036566 epidermal hyperplasia Effects 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361914088P | 2013-12-10 | 2013-12-10 | |
| US61/914,088 | 2013-12-10 | ||
| PCT/US2014/069453 WO2015089131A1 (en) | 2013-12-10 | 2014-12-10 | Alkylpyrazolyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016539983A JP2016539983A (ja) | 2016-12-22 |
| JP2016539983A5 true JP2016539983A5 (OSRAM) | 2018-01-25 |
Family
ID=53371788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016537963A Pending JP2016539983A (ja) | 2013-12-10 | 2014-12-10 | アルキルピラゾリルグアニジンｆ１ｆ０−ａｔｐアーゼ阻害剤及びその治療用途 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9815791B2 (OSRAM) |
| EP (1) | EP3080088B1 (OSRAM) |
| JP (1) | JP2016539983A (OSRAM) |
| AU (1) | AU2014363958B2 (OSRAM) |
| CA (1) | CA2931850A1 (OSRAM) |
| WO (1) | WO2015089131A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20171280T1 (hr) | 2010-12-08 | 2018-01-12 | Lycera Corporation | Pirazolilgvanidinski inhibitori f1f0-atpaze i njihova upotreba u terapiji |
| WO2015089152A1 (en) | 2013-12-10 | 2015-06-18 | Lycera Corporation | N-substituted pyrazolyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof |
| CA2931851A1 (en) * | 2013-12-10 | 2015-06-18 | Lycera Corporation | Trifluoromethyl pyrazolyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof |
| CN116570589B (zh) * | 2023-05-30 | 2025-02-11 | 南阳理工学院 | 化合物Parimifasor在制备抗肿瘤药物中的应用 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4977189A (en) | 1986-05-07 | 1990-12-11 | American Cyanamid Company | Substituted guanidinedicarbonyl derivatives |
| JPH07188197A (ja) | 1993-11-17 | 1995-07-25 | Fujisawa Pharmaceut Co Ltd | オキサゾール誘導体 |
| DE4344550A1 (de) | 1993-12-24 | 1995-06-29 | Hoechst Ag | Substituierte 1-Oxo-1,2-dihydro-isochinolinoyl- und 1,1-Dioxo-2H-1,2-benzothiazinoylguanidine, Verfahrenzu ihrer Herstellung, ihre Verwendung als Medikamentt oder Diagnostikum sowie sie enthaltendes Medikamen |
| US7041702B1 (en) | 1997-10-21 | 2006-05-09 | Scion Pharmaceuticals, Inc. | Pharmaceutically active compounds and methods of use |
| JP2002536411A (ja) | 1999-02-09 | 2002-10-29 | ブリストル−マイヤーズ スクイブ カンパニー | Ｘａ因子のラクタム系阻害剤および方法 |
| US7276348B2 (en) | 1999-04-30 | 2007-10-02 | Regents Of The University Of Michigan | Compositions and methods relating to F1F0-ATPase inhibitors and targets thereof |
| CN1202095C (zh) | 1999-07-15 | 2005-05-18 | 住友制药株式会社 | 杂芳环化合物 |
| US6627629B2 (en) | 2000-06-30 | 2003-09-30 | Bristol-Myers Squibb Pharma | N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity |
| AU2002357137A1 (en) | 2001-12-10 | 2003-06-23 | Bristol-Myers Squibb Company | (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial f1f0 atp hydrolase |
| GB0208224D0 (en) | 2002-04-10 | 2002-05-22 | Celltech R&D Ltd | Chemical compounds |
| US20040009972A1 (en) | 2002-06-17 | 2004-01-15 | Ding Charles Z. | Benzodiazepine inhibitors of mitochondial F1F0 ATP hydrolase and methods of inhibiting F1F0 ATP hydrolase |
| US7109224B2 (en) | 2002-11-06 | 2006-09-19 | Bristol-Myers Squibb Co. | Acyl guanidine compounds and use thereof |
| AU2003297629A1 (en) | 2002-12-04 | 2004-06-23 | Ore Pharmaceuticals Inc. | Modulators of melanocortin receptor |
| DE102004008141A1 (de) | 2004-02-19 | 2005-09-01 | Abbott Gmbh & Co. Kg | Guanidinverbindungen und ihre Verwendung als Bindungspartner für 5-HT5-Rezeptoren |
| US20090275099A1 (en) | 2004-04-27 | 2009-11-05 | Regents Of The University Of Michigan | Methods and compositions for treating diseases and conditions associated with mitochondrial function |
| US20050272723A1 (en) | 2004-04-27 | 2005-12-08 | The Regents Of The University Of Michigan | Methods and compositions for treating diseases and conditions associated with mitochondrial function |
| EP1765325A4 (en) | 2004-07-01 | 2009-08-12 | Synta Pharmaceuticals Corp | HETEROARYL COMPOUNDS SUBSTITUTED IN 2 |
| EP2418206A3 (en) | 2006-06-09 | 2012-06-27 | The Regents of the University of Michigan | Benzodiazepine derivatives useful in the treatment of autoimmune disorders |
| WO2009036175A2 (en) | 2007-09-14 | 2009-03-19 | The Regents Of The University Of Michigan | F1f0-atpase inhibitors and related methods |
| JP2011507910A (ja) | 2007-12-21 | 2011-03-10 | ユニバーシティー オブ ロチェスター | 真核生物の寿命を変更するための方法 |
| KR100982661B1 (ko) | 2008-04-22 | 2010-09-17 | 전남대학교산학협력단 | 플라스멥신 ⅱ 활성을 저해하는 화합물을 유효성분으로함유하는 말라리아 예방 및 치료를 위한 약학 조성물 및이를 이용한 말라리아 치료방법 |
| US8497307B2 (en) | 2008-09-11 | 2013-07-30 | The Regents Of The University Of Michigan | Aryl guanidine F1F0-ATPase inhibitors and related methods |
| AU2011338302A1 (en) * | 2010-12-08 | 2013-07-11 | Lycera Corporation | Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof |
| HRP20171280T1 (hr) | 2010-12-08 | 2018-01-12 | Lycera Corporation | Pirazolilgvanidinski inhibitori f1f0-atpaze i njihova upotreba u terapiji |
| US9169199B2 (en) | 2010-12-08 | 2015-10-27 | Lycera Corporation | Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof |
| CA2820044A1 (en) * | 2010-12-08 | 2012-06-14 | Lycera Corporation | Pyridonyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof |
| WO2013185048A2 (en) | 2012-06-08 | 2013-12-12 | Lycera Corporation | Heterocyclic guanidine f1f0-atpase inhibitors and therapeutic uses thereof |
| WO2013185045A1 (en) | 2012-06-08 | 2013-12-12 | Lycera Corporation | Indazole guanidine f1f0-atpase inhibitors and therapeutic uses thereof |
| US9580391B2 (en) | 2012-06-08 | 2017-02-28 | Lycera Corporation | Saturated acyl guanidine for inhibition of F1F0-ATPase |
| WO2015089152A1 (en) * | 2013-12-10 | 2015-06-18 | Lycera Corporation | N-substituted pyrazolyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof |
| CA2931851A1 (en) | 2013-12-10 | 2015-06-18 | Lycera Corporation | Trifluoromethyl pyrazolyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof |
-
2014
- 2014-12-10 JP JP2016537963A patent/JP2016539983A/ja active Pending
- 2014-12-10 CA CA2931850A patent/CA2931850A1/en not_active Abandoned
- 2014-12-10 AU AU2014363958A patent/AU2014363958B2/en not_active Ceased
- 2014-12-10 US US15/101,129 patent/US9815791B2/en not_active Expired - Fee Related
- 2014-12-10 EP EP14869679.2A patent/EP3080088B1/en not_active Not-in-force
- 2014-12-10 WO PCT/US2014/069453 patent/WO2015089131A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY187617A (en) | Bridged ring compounds as hepatitis c virus (hcv) inhibitors and pharmaceutical applications thereof | |
| JP2012092103A5 (OSRAM) | ||
| JP2015531773A5 (OSRAM) | ||
| EA201401063A1 (ru) | Алкил 2-{[(2r,3s,5r)-5-(4-амино-2-оксо-2h-пиримидин-1-ил)-3-гидрокситетрагидрофуран-2-илметокси]феноксифосфориламино}пропионаты, нуклеозидные ингибиторы рнк-полимеразы hcv ns5b, способы их получения и применения | |
| JP2017511357A5 (OSRAM) | ||
| JP2016540742A5 (OSRAM) | ||
| JP2017509689A5 (OSRAM) | ||
| EA201492250A1 (ru) | Гетероциклическое соединение | |
| JP2016518437A5 (OSRAM) | ||
| JP2014509647A5 (OSRAM) | ||
| JP2019501125A5 (OSRAM) | ||
| AR089671A1 (es) | 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| JP2013507448A5 (OSRAM) | ||
| AR092790A1 (es) | Derivados bencimidazolicos del acido hidroxamico | |
| JP2019530699A5 (OSRAM) | ||
| JP2016518385A5 (OSRAM) | ||
| JP2015516427A5 (OSRAM) | ||
| JP2017533263A5 (OSRAM) | ||
| JP2016507581A5 (OSRAM) | ||
| JP2020500916A5 (OSRAM) | ||
| RU2018113718A (ru) | Новые соединения | |
| JP2012502111A5 (OSRAM) | ||
| JP2018501215A5 (OSRAM) | ||
| JP2016529315A5 (OSRAM) | ||
| JP2016539983A5 (OSRAM) |